PURPOSE: Intensive surveillance after curative treatment of colorectal cancer (CRC) is associated with improved overall survival. This study examined concordance with the 2005 ASCO surveillance guidelines at the population level. METHODS: A cohort of 250 patients diagnosed with stage II or III CRC in 2004 and alive 42 months after diagnosis was identified from health administrative data in Manitoba, Canada. Colonoscopy, liver imaging, and carcinoembryonic antigen (CEA) testing were assessed over 3 years. Guidelines were met if patients had at least one colonoscopy in 3 years and at least one liver imaging test and three CEA tests annually. Multivariate logistic regression assessed the effect of patient and physician characteristics and disease and treatment factors on guideline concordance. RESULTS: Guidelines for colonoscopy, liver imaging, and CEA were met by 80.4%, 47.2%, and 22% of patients, respectively. Guideline concordance for colonoscopy was predicted by annual contact with a surgeon, higher income, and the diagnosis of colon (rather than rectal) cancer. Adherence was lower in those older than 70 years and with higher comorbidity. For liver imaging, significant predictors were annual contact with an oncologist, receipt of chemotherapy, and diagnosis of colon cancer. Concordance with CEA guidelines was higher with annual contact with an oncologist and high levels of family physician contact, and lower in urban residents, in those older than 70, and in those with stage II disease. CONCLUSION: Completion of recommended liver imaging and CEA testing fall well below guidelines in Manitoba, whereas colonoscopy is better provided. Addressing this gap should improve outcomes for CRC survivors.
PURPOSE: Intensive surveillance after curative treatment of colorectal cancer (CRC) is associated with improved overall survival. This study examined concordance with the 2005 ASCO surveillance guidelines at the population level. METHODS: A cohort of 250 patients diagnosed with stage II or III CRC in 2004 and alive 42 months after diagnosis was identified from health administrative data in Manitoba, Canada. Colonoscopy, liver imaging, and carcinoembryonic antigen (CEA) testing were assessed over 3 years. Guidelines were met if patients had at least one colonoscopy in 3 years and at least one liver imaging test and three CEA tests annually. Multivariate logistic regression assessed the effect of patient and physician characteristics and disease and treatment factors on guideline concordance. RESULTS: Guidelines for colonoscopy, liver imaging, and CEA were met by 80.4%, 47.2%, and 22% of patients, respectively. Guideline concordance for colonoscopy was predicted by annual contact with a surgeon, higher income, and the diagnosis of colon (rather than rectal) cancer. Adherence was lower in those older than 70 years and with higher comorbidity. For liver imaging, significant predictors were annual contact with an oncologist, receipt of chemotherapy, and diagnosis of colon cancer. Concordance with CEA guidelines was higher with annual contact with an oncologist and high levels of family physician contact, and lower in urban residents, in those older than 70, and in those with stage II disease. CONCLUSION: Completion of recommended liver imaging and CEA testing fall well below guidelines in Manitoba, whereas colonoscopy is better provided. Addressing this gap should improve outcomes for CRC survivors.
Authors: Erin G Stone; Sally C Morton; Marlies E Hulscher; Margaret A Maglione; Elizabeth A Roth; Jeremy M Grimshaw; Brian S Mittman; Lisa V Rubenstein; Laurence Z Rubenstein; Paul G Shekelle Journal: Ann Intern Med Date: 2002-05-07 Impact factor: 25.391
Authors: Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Jennifer L Spratlin; David Hui; John Hanson; Charles Butts; Heather-Jane Au Journal: Clin Colorectal Cancer Date: 2008-03 Impact factor: 4.481
Authors: Alvaro Figueredo; R Bryan Rumble; Jean Maroun; Craig C Earle; Bernard Cummings; Robin McLeod; Lisa Zuraw; Caroline Zwaal Journal: BMC Cancer Date: 2003-10-06 Impact factor: 4.430
Authors: Christina E Bailey; Chung-Yuan Hu; Y Nancy You; Harmeet Kaur; Randy D Ernst; George J Chang Journal: J Oncol Pract Date: 2015-04-07 Impact factor: 3.840
Authors: Montika Bush; Ross J Simpson; Anna Kucharska-Newton; Gang Fang; Til Stürmer; M Alan Brookhart Journal: Med Care Date: 2018-07 Impact factor: 2.983
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442
Authors: Thijs Wieldraaijer; Pascal Bruin; Laura A M Duineveld; Pieter J Tanis; Anke B Smits; Henk C P M van Weert; Jan Wind Journal: Dig Surg Date: 2017-03-14 Impact factor: 2.588
Authors: Patrick E Young; Craig M Womeldorph; Eric K Johnson; Justin A Maykel; Bjorn Brucher; Alex Stojadinovic; Itzhak Avital; Aviram Nissan; Scott R Steele Journal: J Cancer Date: 2014-03-15 Impact factor: 4.207
Authors: Jennifer R Tomasone; Melissa C Brouwers; Marija Vukmirovic; Eva Grunfeld; Mary Ann O'Brien; Robin Urquhart; Melanie Walker; Fiona Webster; Margaret Fitch Journal: ESMO Open Date: 2016-09-06
Authors: Marvella E Ford; Katherine R Sterba; Kent Armeson; Angela M Malek; Kendrea D Knight; Jane Zapka Journal: J Cancer Educ Date: 2019-10 Impact factor: 1.771